PET imaging of dopamine transporters with [ 18 F]FE-PE2I: Effects of anti-Parkinsonian drugs

Bang, Ji In; Jung, In Soon; Song, Yoo Sung; Park, Hyun Soo; Moon, Byung Seok; Lee, Byung Chul; Kim, Sang Eun

doi:10.1016/j.nucmedbio.2015.11.002

Cited by 16 publications

(13 citation statements)

References 51 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of [ 18 F]FE-PE2I is preferable due to the higher selectivity for DAT. [ 123 I]FP-CIT binding is susceptible to the use of selective serotonin reuptake inhibitors (SSRI) [ 11 ], although pre-scan drug withdrawal per se is not required in a clinical setting [ 38 ]. The improved logistics when using the shorter 30–40-min protocol with [ 18 F]FE-PE2I PET as compared to [ 123 I]FP-CIT SPECT decreases the overall time spent by the patients, their relatives and the staff (Table 1 ) and allows for an optimized and efficient use of scanner and waiting room facilities.…”

Section: Discussionmentioning

confidence: 99%

[18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism

et al. 2022

View full text Add to dashboard Cite

Background Dopamine transporter (DAT) imaging of striatum is clinically used in Parkinson’s disease (PD) and neurodegenerative parkinsonian syndromes (PS) especially in the early disease stages. The aim of the present study was to evaluate the diagnostic performance of the recently developed tracer for DAT imaging [18F]FE-PE2I PET/CT to the reference standard [123I]FP-CIT SPECT. Methods Ninety-eight unselected patients referred for DAT imaging were included prospectively and consecutively and evaluated with [18F]FE-PE2I PET/CT and [123I]FP-CIT SPECT on two separate days. PET and SPECT scans were categorized independently by two blinded expert readers as either normal, vascular changes, or mixed. Semiquantitative values were obtained for each modality and compared regarding effect size using Glass’ delta. Results Fifty-six of the [123I]FP-CIT SPECT scans were considered abnormal (52 caused by PS, 4 by infarctions). Using [18F]FE-PE2I PET/CT, 95 of the 98 patients were categorized identically to SPECT as PS or non-PS with a sensitivity of 0.94 [0.84–0.99] and a specificity of 1.00 [0.92–1.00]. Inter-reader agreement for [18F]FE-PE2I PET with a kappa of 0.97 [0.89–1.00] was comparable to the agreement for [123I]FP-CIT SPECT of 0.96 [0.76–1.00]. Semiquantitative values for short 10-min reconstructions of [18F]FE-PE2I PET/CT were comparable to longer reconstructions. The effect size for putamen/caudate nucleus ratio was significantly increased using PET compared to SPECT. Conclusions The high correspondence of [18F]FE-PE2I PET compared to reference standard [123I]FP-CIT SPECT establishes [18F]FE-PE2I PET as a feasible PET tracer for clinical use with favourable scan logistics.

show abstract

Section: Discussionmentioning

confidence: 99%

[18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Using an automatic synthesizer system (GE TRACERlab FX2 N), radioactive 18 F nuclei were produced by a cyclotron. After separation, the tosylethyl-PE2I precursor was dissolved in anhydrous dimethyl sulfoxide, and reacted with k [ 18 F]/ Kryptofix2.2.2 at −140° for 5 min, followed by purification using high-performance liquid chromatography with a C18 column, to obtain the PET ligand, [ 18 F]FE-PE2I. , Separate sets of MitoPark mice aged 8, 12, 16, and 20 weeks were scanned. Tail vein injections of 0.3 mCi [ 18 F]FE-PE2I were performed during anesthesia (5% isoflurane/oxygen mixture for induction, 2% for maintenance).…”

Section: Methodsmentioning

confidence: 99%

Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease

Wang

Kuo

Huang

et al. 2021

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

GLP-1 agonists have become increasingly interesting as a new Parkinson’s disease (PD) clinical treatment strategy. Additional preclinical studies are important to validate this approach and define the disease stage when they are most effective. We hence characterized the efficacy of PT320, a sustained release formulation of the long acting GLP-1 agonist, exenatide, in a progressive PD (MitoPark) mouse model. A clinically translatable biweekly PT320 dose was administered starting at 5 weeks of age and longitudinally evaluated to 24 weeks, and multiple behavioral/cellular parameters were measured. PT320 significantly improved spontaneous locomotor activity and rearing in MitoPark PD mice. “Motivated” behavior also improved, evaluated by accelerating rotarod performance. Behavioral improvement was correlated with enhanced cellular and molecular indices of dopamine (DA) midbrain function. Fast scan cyclic voltammetry demonstrated protection of striatal and nucleus accumbens DA release and reuptake in PT320 treated MitoPark mice. Positron emission tomography showed protection of striatal DA fibers and tyrosine hydroxylase protein expression was augmented by PT320 administration. Early PT320 treatment may hence provide an important neuroprotective therapeutic strategy in PD.

show abstract

“…[ 18 F] DOPA was synthesized and provided by the Department of Nuclear Medicine affiliated with National Taiwan University Hospital. [ 18 F] FE-PE2I was synthesized as previously reported, with some modifications [46]. Briefly, nucleophilic fluorination of a tosyl precursor was performed in dimethyl sulfoxide with dried K [1 8F]/K 2.2.2 , followed by modified HPLC purification (without a pre-purified cartridge).…”

Section: Methodsmentioning

confidence: 99%

The Effect of Sertoli Cells on Xenotransplantation and Allotransplantation of Ventral Mesencephalic Tissue in a Rat Model of Parkinson’s Disease

Jhao

Chiu

Chen

et al. 2019

Cells

View full text Add to dashboard Cite

Intra-striatal transplantation of fetal ventral mesencephalic (VM) tissue has a therapeutic effect on patients with Parkinson’s disease (PD). Sertoli cells (SCs) possess immune-modulatory properties that benefit transplantation. We hypothesized that co-graft of SCs with VM tissue can attenuate rejection. Hemi-parkinsonian rats were generated by injecting 6-hydroxydopamine into the right medial forebrain bundle of Sprague Dawley (SD) rats. The rats were then intrastriatally transplanted with VM tissue from rats or pigs (rVM or pVM), with/without a co-graft of SCs (rVM+SCs or pVM+SCs). Recovery of dopaminergic function and survival of the grafts were evaluated using the apomorphine-induced rotation test and small animal-positron emission tomography (PET) coupled with [18F] DOPA or [18F] FE-PE2I, respectively. Immunohistochemistry (IHC) examination was used to determine the survival of the grafted dopaminergic neurons in the striatum and to investigate immune-modulatory effects of SCs. The results showed that the rVM+SCs and pVM+SCs groups had significantly improved drug-induced rotational behavior compared with the VM alone groups. PET revealed a significant increase in specific uptake ratios (SURs) of [18F] DOPA and [18F] FE-PE2I in the grafted striatum of the rVM+SCs and pVM+SCs groups as compared to that of the rVM and pVM groups. SC and VM tissue co-graft led to better dopaminergic (DA) cell survival. The co-grafted groups exhibited lower populations of T-cells and activated microglia compared to the groups without SCs. Our results suggest that co-graft of SCs benefit both xeno- and allo-transplantation of VM tissue in a PD rat model. Use of SCs enhanced the survival of the grafted dopaminergic neurons and improved functional recovery. The enhancement may in part be attributable to the immune-modulatory properties of SCs. In addition, [18F]DOPA and [18F]FE-PE2I coupled with PET may provide a feasible method for in vivo evaluation of the functional integrity of the grafted DA cell in parkinsonian rats.

show abstract

PET imaging of dopamine transporters with [ 18 F]FE-PE2I: Effects of anti-Parkinsonian drugs

Abstract: on lesioned and unlesioned striatal BPND was also assessed in the PD rats. Results:The BPND was significantly lower in the lesioned striatum than in the iii

Cited by 16 publications

References 51 publications

[18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism

[18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism

Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease

The Effect of Sertoli Cells on Xenotransplantation and Allotransplantation of Ventral Mesencephalic Tissue in a Rat Model of Parkinson’s Disease

Contact Info

Product

Resources

About